Alhemo(Concizumab) Instructions:Uses,Dosage, Side Effects

1 / 1

Alhemo(Concizumab)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Novo Nordisk

Formulation:

INJECTION

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Alhemo is a novel prophylactic treatment for adult and pediatric patients aged 12 years and older with hemophilia A or B, specifically in those with inhibitors to FVIII or FIX. As a tissue factor pathway inhibitor (TFPI) antagonist, it works by modulating the clotting cascade to prevent bleeding episodes in these high-risk patients. Alhemo’s formulation, administered subcutaneously, ensures a regular dosing regimen with individualized adjustments based on plasma concentration levels.

This medication provides a vital therapeutic option for hemophilia patients who are resistant to traditional clotting factor treatments, offering hope for improved disease management and quality of life.

Generic name

Alhemo(Concizumab)

English name

Concizumab

Alternative Names

Alhemo

Drug prices

Indications

Alhemo(Concizumab) is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with:

Hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors;

Hemophilia B (congenital factor IX deficiency) with FIX inhibitors.

Therapeutic Target

Alhemo is a tissue factor pathway inhibitor (TFPI) antagonist, targeting the coagulation cascade to prevent bleeding episodes in hemophilia patients with inhibitors against FVIII or FIX.

Active Ingredients

Concizumab-mtci

Dosage form

INJECTION

specifications

150 mg/1.5ml/box

Description

Concizumab-mtci is a humanized IgG4 monoclonal antibody, synthesized using recombinant DNA technology in Chinese Hamster Ovary (CHO) cells, with an estimated molecular weight of 149 kDa.

Alhemo (concizumab-mtci) injection appears as a clear to slightly opalescent, colorless to faintly yellow solution, which may contain translucent to white particles. This medication is provided in a prefilled pen for subcutaneous administration, designed for single-patient use.

The Alhemo prefilled pen is available in the following formulations:

- 60 mg/1.5 mL, with 40 mg of the active ingredient per 1 mL.

- 150 mg/1.5 mL, with 100 mg of the active ingredient per 1 mL.

- 300 mg/3 mL, with 100 mg of the active ingredient per 1 mL.

Each 1 mL of Alhemo prefilled pen also contains the following excipients: arginine hydrochloride (5.27 mg), histidine (5.12 mg), phenol (3.5 mg), polysorbate 80 (0.25 mg), sodium chloride (1.46 mg), sucrose (51.3 mg), and water for injection. The pH of the solution is adjusted to 6.0 using hydrochloric acid and sodium hydroxide.

Dosage and Administration

Alhemo should be administered by subcutaneous injection to the abdomen or thigh, with daily rotation of injection sites. The recommended dosing regimen is as follows:

- Day 1: Loading dose of 1 mg/kg

- Day 2 and onwards: Once-daily dose of 0.2 mg/kg until the dose is individualized based on plasma concentration measurements.

After 4 weeks of treatment, plasma concentration of concizumab-mtci should be measured before the next dose using an enzyme-linked immunosorbent assay (ELISA).

CATEGORY NAVIGATION